MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596274 | Name: Jom 13

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Jom 13 is a cyclic delta receptor selective tetrapeptide.

Chemical Structure

Jom 13
Jom 13
CAS#117550-12-6

Theoretical Analysis

MedKoo Cat#: 596274

Name: Jom 13

CAS#: 117550-12-6

Chemical Formula: C26H34N4O6S2

Exact Mass: 562.1920

Molecular Weight: 562.70

Elemental Analysis: C, 55.50; H, 6.09; N, 9.96; O, 17.06; S, 11.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Jom 13; H-Tyrosyl-cyclo(cysteinyl-phenylalanyl-penicillaminyl)-OH; DCFPE; Htdcpdp-OH;
IUPAC/Chemical Name
(S)-2-((S)-2-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-3-mercaptopropanamido)-3-phenylpropanoic (S)-2-amino-3-mercapto-3-methylbutanoic anhydride
InChi Key
LINHQEFGHROEAQ-BURNTYAHSA-N
InChi Code
InChI=1S/C26H34N4O6S2/c1-26(2,38)21(28)25(35)36-24(34)19(13-15-6-4-3-5-7-15)29-23(33)20(14-37)30-22(32)18(27)12-16-8-10-17(31)11-9-16/h3-11,18-21,31,37-38H,12-14,27-28H2,1-2H3,(H,29,33)(H,30,32)/t18-,19-,20+,21-/m0/s1
SMILES Code
CC([C@@H](N)C(OC([C@@H](NC([C@H](NC([C@@H](N)Cc1ccc(O)cc1)=O)CS)=O)Cc2ccccc2)=O)=O)(S)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 562.70 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH. Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 2006 Jan 19;1069(1):172-81. Epub 2005 Dec 20. PubMed PMID: 16364263; PubMed Central PMCID: PMC1780167. 2: Mosberg HI, Fowler CB. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity. J Pept Res. 2002 Dec;60(6):329-35. PubMed PMID: 12464111. 3: Mosberg HI. Complementarity of delta opioid ligand pharmacophore and receptor models. Biopolymers. 1999;51(6):426-39. Review. PubMed PMID: 10797231. 4: Mansour A, Taylor LP, Fine JL, Thompson RC, Hoversten MT, Mosberg HI, Watson SJ, Akil H. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem. 1997 Jan;68(1):344-53. PubMed PMID: 8978745. 5: Mosberg HI, Dua RK, Pogozheva ID, Lomize AL. Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain. Biopolymers. 1996 Sep;39(3):287-96. PubMed PMID: 8756510. 6: Gao P. Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study. J Comput Aided Mol Des. 1996 Aug;10(4):327-36. PubMed PMID: 8877704. 7: Brandt W, Stoldt M, Schinke H. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors. J Comput Aided Mol Des. 1996 Jun;10(3):201-12. PubMed PMID: 8808737. 8: Lomize AL, Pogozheva ID, Mosberg HI. Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands. Biopolymers. 1996 Feb;38(2):221-34. PubMed PMID: 8589255. 9: Deschamps JR, George C, Flippen-Anderson JL. Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies. Biopolymers. 1996;40(1):121-39. Review. PubMed PMID: 8541444. 10: Mosberg HI, Omnaas JR, Lomize A, Heyl DL, Nordan I, Mousigian C, Davis P, Porreca F. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994 Dec 9;37(25):4384-91. PubMed PMID: 7996550. 11: Mosberg HI, Lomize AL, Wang C, Kroona H, Heyl DL, Sobczyk-Kojiro K, Ma W, Mousigian C, Porreca F. Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J Med Chem. 1994 Dec 9;37(25):4371-83. PubMed PMID: 7996549. 12: Heyl DL, Schmitter SJ, Bouzit H, Johnson TW, Hepp AM, Kurtz KR, Mousigian C. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity. Int J Pept Protein Res. 1994 Nov;44(5):420-6. PubMed PMID: 7896499. 13: Mosberg HI, Kroona HB. Incorporation of a novel conformationally restricted tyrosine analog into a cyclic, delta opioid receptor selective tetrapeptide (JOM-13) enhances delta receptor binding affinity and selectivity. J Med Chem. 1992 Nov 13;35(23):4498-500. PubMed PMID: 1333014. 14: Heyl DL, Mosberg HI. Modification of the Phe3 aromatic moiety in delta receptor-selective dermorphin/deltorphin-related tetrapeptides. Effects on opioid receptor binding. Int J Pept Protein Res. 1992 May;39(5):450-7. PubMed PMID: 1330964. 15: Nikiforovich GV, Hruby VJ, Prakash O, Gehrig CA. Topographical requirements for delta-selective opioid peptides. Biopolymers. 1991 Jul;31(8):941-55. PubMed PMID: 1782355. 16: Heyl DL, Omnaas JR, Sobczyk-Kojiro K, Medzihradsky F, Smith CB, Mosberg HI. Opioid receptor affinity and selectivity effects of second residue and carboxy terminal residue variation in a cyclic disulfide-containing opioid tetrapeptide. Int J Pept Protein Res. 1991 Mar;37(3):224-9. PubMed PMID: 1651290.

View History

VU0364739

VU0364739

Featured